GlaxoSmithKline Pharmaceuticals Limited (GSK India) is a leading pharmaceutical company with a presence in India for over a century and a subsidiary of global healthcare leader GSK plc.
 |
| Figure 1 |
The
company focuses on specialty medicines and established healthcare brands,
delivering strong financial performance, with annual revenue of ₹3,723 crore
and net profit before exceptional items of ₹915 crore, reflecting year-on-year
growth of 8.6% and 32%, respectively.
Let us now turn to the Elliott
Wave analysis of the GSK
India
stock chart to understand its current price structure and the possible path
ahead.
 |
| Figure 2 |
Since its listing, GlaxoSmithKline Pharmaceuticals Limited has witnessed a prolonged upward movement, with its monthly chart displaying a well-defined bullish price structure.
From an Elliott Wave perspective, the advance can be interpreted as a completed five-wave impulsive cycle, labelled Waves (1) through (5) on the chart.
Following the completion of
this cycle, the stock entered a prolonged corrective phase. On a higher time
frame, we may therefore consider the completed impulsive advance as Primary
Wave 1 and the subsequent correction as Primary Wave 2 of a larger
bullish cycle.
 |
| Figure 3 |
From an Elliott Wave perspective, the chart suggests that GlaxoSmithKline Pharmaceuticals may be developing a larger impulsive structure. While the earlier advance can be counted as Wave 1, followed by a corrective Wave 2, the subsequent rally appears to contain Waves 3 and 4 of the larger cycle.
The key question is whether Wave 3 has completed
its five sub-waves and what stage Wave 4 has reached. These aspects will be
examined in the following chart to assess the stock’s current Elliott Wave
structure and the potential for a subsequent Wave 5 advance.
 |
| Figure 4 |
In the previous chart, we
identified Waves 1, 2, and 3 of the larger impulsive structure. To confirm the
completion of Wave 3, we examined its internal sub-waves, which appear to form
a complete five-wave sequence. Notably, Sub-Wave 3 terminates precisely at the 223.6%
Fibonacci extension level, supporting our wave count. Therefore, the internal
structure suggests that the larger Wave 3 may also be complete.
 |
| Figure 5 |
After the larger Wave 3 completes, the weekly chart shows a corrective phase, with the decline retracing toward the previous internal Wave 4 region before recovering. This movement may represent an A–B–C corrective pattern.
Wave A appears complete, while Wave B is still developing as a three-wave structure, with sub-waves (a) and (b) formed and sub-wave (c) yet to unfold. The retracement of sub-wave (b) has approached the 61.8% Fibonacci level of sub-wave (a).
If this count holds, sub-wave (b) may advance further to complete its structure
before Wave C resumes the broader correction. This remains a tentative Elliott
Wave interpretation, subject to confirmation by subsequent price action.
 |
| Figure 6 |
The weekly chart suggests that sub-wave (b) of the larger Wave B has retraced approximately 61.8% of sub-wave (a). If the expected pattern unfolds, the price may rise to complete sub-wave (c), thereby completing Wave B.
A subsequent decline could then form
Wave C of the larger corrective Wave 4, followed by a potential upward move in
Wave 5. The blue arrows illustrate this possible scenario, not a confirmed
forecast. We must closely monitor actual price action to validate the Elliott
Wave count and confirm whether this projected sequence unfolds as anticipated.
This concludes my Elliott Wave analysis of
GlaxoSmithKline Pharmaceuticals Limited for now. The next phase will depend on
how price moves. Only subsequent price action will reveal
how accurately our Elliott Wave count reflects the market structure.
Disclaimer: The information and Elliott Wave analysis
presented in this article are intended solely for educational and informational
purposes. They represent the author's interpretation of market price action and
should not be considered as investment, financial, or trading advice. The
author is not a SEBI-registered Investment Adviser or Research Analyst. Readers
should conduct their own research and consult a SEBI-registered financial
professional before making any investment decisions. Investing in the stock
market involves risk, and past performance does not guarantee future results.